| __timestamp | Bausch Health Companies Inc. | Bristol-Myers Squibb Company |
|---|---|---|
| Wednesday, January 1, 2014 | 246000000 | 4534000000 |
| Thursday, January 1, 2015 | 582800000 | 5920000000 |
| Friday, January 1, 2016 | 455000000 | 4940000000 |
| Sunday, January 1, 2017 | 366000000 | 6411000000 |
| Monday, January 1, 2018 | 414000000 | 6345000000 |
| Tuesday, January 1, 2019 | 471000000 | 6148000000 |
| Wednesday, January 1, 2020 | 452000000 | 11143000000 |
| Friday, January 1, 2021 | 465000000 | 10195000000 |
| Saturday, January 1, 2022 | 529000000 | 9509000000 |
| Sunday, January 1, 2023 | 604000000 | 9299000000 |
| Monday, January 1, 2024 | 11159000000 |
Cracking the code
In the competitive world of pharmaceuticals, innovation is key to staying ahead. Over the past decade, Bristol-Myers Squibb Company (BMY) and Bausch Health Companies Inc. (BHC) have demonstrated contrasting approaches to research and development (R&D) spending. From 2014 to 2023, BMY consistently allocated a significant portion of its resources to R&D, with expenditures peaking in 2020 at over 11 billion dollars. This represents a staggering 145% increase from their 2014 spending. In contrast, BHC's R&D investment, while growing, remained relatively modest, with a peak in 2023 at 604 million dollars, marking a 145% increase from 2014. This disparity highlights BMY's commitment to innovation, investing nearly 15 times more than BHC in 2023. As the pharmaceutical landscape evolves, these strategic choices in R&D spending will likely shape the future of both companies.
Explore how R&D spending shapes pharmaceutical innovation.
Who Prioritizes Innovation? R&D Spending Compared for Amgen Inc. and Bristol-Myers Squibb Company
Bristol-Myers Squibb Company vs Gilead Sciences, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Bristol-Myers Squibb Company and Zoetis Inc. Allocate Funds
Bristol-Myers Squibb Company or BeiGene, Ltd.: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Bristol-Myers Squibb Company and Alkermes plc
Comparing Innovation Spending: Bristol-Myers Squibb Company and Catalyst Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. or Bausch Health Companies Inc.: Who Invests More in Innovation?
Research and Development Investment: Teva Pharmaceutical Industries Limited vs Bausch Health Companies Inc.
R&D Spending Showdown: Incyte Corporation vs Bausch Health Companies Inc.
Who Prioritizes Innovation? R&D Spending Compared for Corcept Therapeutics Incorporated and Bausch Health Companies Inc.
R&D Spending Showdown: Viking Therapeutics, Inc. vs Bausch Health Companies Inc.
Research and Development Expenses Breakdown: Rhythm Pharmaceuticals, Inc. vs Bausch Health Companies Inc.